FindTrial
Sign In

Trastuzumab deruxtecan (DS-8201a)

DRUG3 trials

Sponsors

Daiichi Sankyo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions

Breast CancerBreast Cancer MetastaticBreast Cancer Stage IVBreast Cancer With Bone MetastasisBreast Cancer With Metastatic Bone DiseaseBreast CarcinomaBreast NeoplasmsHER2

Phase 1

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Active, not recruitingNCT04042701
Daiichi SankyoBreast Cancer, Non-small Cell Lung Carcinoma
Start: 2020-02-10End: 2027-03-31Target: 115Updated: 2025-11-18

Phase 3

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Active, not recruitingNCT03734029
Daiichi SankyoBreast Cancer
Start: 2018-12-27End: 2026-08-01Updated: 2025-10-06

Unknown Phase

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
RecruitingNCT07030569
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoBreast Cancer, Breast Cancer Metastatic, Breast Cancer Stage IV +13
Start: 2024-02-01End: 2027-01-01Target: 500Updated: 2025-06-22

Related Papers

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
2025-10-086 citations
Abstract P5-07-29: Trastuzumab deruxtecan With Pembrolizumab in Previously Treated HER2-Expressing Advanced or Metastatic Breast Cancer: Interim Analyses of the Breast Cohorts from the Open-Label, Multicenter, Phase 1b Study DS8201-A-U106
Clinical Cancer Research2025-06-131 citations
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.
2025-05-155 citations
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
The Oncologist2025-05-019 citations
Abstract 5928: Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Cancer Research2025-04-211 citations
Abstract 6364: Serum proteomics analysis: Potential biomarkers and mechanisms of trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis (ILD)
Cancer Research2025-04-211 citations
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
2024-11-2516 citations
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
2024-06-1712 citations
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.
Journal of Clinical Oncology2024-06-017 citations
188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC)
ESMO Open2024-05-012 citations
Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
2024-03-0310 citations
A Clinical Case of Successful Treatment of HER2-Low Disseminated Breast Cancer with Trastuzumab Deruxtecan
Voprosy Onkologii2023-09-02
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
2023-08-0860 citations
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.
Journal of Clinical Oncology2023-06-0111 citations
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
2023-05-1949 citations
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
ESMO Open2023-05-019 citations
192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
ESMO Open2023-05-013 citations
SA 6.1 Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer
The Breast2023-03-14
Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study
Cancer Research2023-03-0126 citations
Abstract HER2-15: HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer
Cancer Research2023-03-011 citations

13 more papers not shown